Weekly-Round-Up-January 2nd to January 8th
January 9, 2023
Apnimed, a clinical-stage pharmaceutical company specializing in the creation of oral pharmaceutical therapies for the management of obstructive sleep apnea (OSA) and associated disorders, announced that it had raised $79.75 million in an oversubscribed financing round, bringing the total amount of its Series C financing to $142.25 million. Alpha Wave Ventures led the financing, which also included existing investors Sectoral Asset Management, Columbia-Seligman Investments, and Tao Capital Partners.
Nexus announced a $150 million equity raise. Cox Enterprises, which focuses on developing the world’s most innovative cleantech and environmental sustainability businesses, led the round and will become the majority owner. These funds will be used to help Nexus Circular’s market-leading advanced recycling process expand in order to meet recycled-plastic commitments. Nexus has produced and commercially sold high-quality, ISCC PLUS certified circular products made from landfill-bound plastics on a consistent basis, diverting over seven million pounds to date.
Belharra Therapeutics, Inc. emerged from stealth mode with an innovative photoaffinity-based chemoproteomics technology capable of identifying non-covalent, small molecule therapeutic candidates for any protein. Versant Ventures, the business’s original investor, contributed $50 million to the company’s Series A financing. Additionally, the company announced a multi-year partnership with Genentech, a member of the Roche Group, which will provide $80 million in upfront capital over the course of the partnership.
Glowbar, a skincare startup whose personalized 30-minute, $65. clinical-grade facial has helped it become a breakout success in New York, has announced a $10 million growth investment headed by Peterson Partners, a Salt Lake City-based firm whose previous investments include Allbirds, solidcore, Bonobos, Rails Clothing, and Madison Reed.
Perceive Biotherapeutics, a biotech firm pioneering breakthrough technologies and therapies in ophthalmology, announced the completion of a $78M Series B fundraising round led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), joining existing Series A investor Deerfield Management and new investors Braidwell LP, the Retinal Degeneration Fund, and Catalio Capital Management, LP.
Cardiac Dimensions, a pioneer in the development of novel, minimally invasive treatment methods for heart failure and related cardiovascular diseases, announced the completion of a $35 million Series D fundraising transaction. Horizon 3 Healthcare and an unnamed strategic investor co-led the financing, with all other previous investors participating, including Arboretum Ventures, Hostplus, EQT Life Sciences (formerly LSP), Lumira Ventures, and M. H. Carnegie & Co.
Immune-Onc Therapeutics, a private, clinical-stage cancer immunotherapy business developing innovative biotherapeutics targeting myeloid checkpoints, announced the closing of an additional $25 million in Series B financing, bringing the total Series B financing to $131 million. This extension was spearheaded by existing investor Triwise Capital, with involvement from new investors such as Proxima Ventures. Furthermore, The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP) and Wuxi Biologics HealthCare Venture have made ongoing strategic capital investments in the company.
Synthekine Inc., a startup developing modified cytokine therapies, announces the completion of a $100 million Series C fundraising headed by The Column Group, including participation from both new and existing investors.The company guides precise protein engineering with immunological insights to create breakthrough therapies for cancer and autoimmune illnesses.
Related Links:
Weekly Round-Up – Dec 12 to Dec 18
Weekly Round-Up – Dec 19 to Dec 25
